The Current Situation and Suggestions of ABO-mismatched Platelet Transfusions

doi:10.3969/j.issn.1671-2587.2024.01.003

JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE ›› 2024, Vol. 26 ›› Issue (1): 17-22.DOI: 10.3969/j.issn.1671-2587.2024.01.003

Previous Articles Next Articles

The Current Situation and Suggestions of ABO-mismatched Platelet Transfusions

YANG Xuexin, WEI Yaming

Department of Blood Transfusion, Guangzhou First People's Hospital, Guangzhou, Guangdong 510180

Received:2023-12-11 Published:2024-03-13

Abstract

Abstract: ABO-mismatched platelet transfusions have been widely used developed country. In recent years, there has been expert consensus on local application in China, but due to the lack of professional knowledge, the safety and effectiveness of ABO-mismatched platelet transfusion are generally concerned, resulting in less application of ABO mismatched platelets in China, even in emergency cases. This paper introduced the concept of ABO mismatched platelet transfusions、red blood cell antigen on platelet、platelet supply imbalance and demand, summarized the research progress of ABO mismatched platelet transfusions in safety and efficacy, suggested the guidance of ABO mismatched platelet transfusions to provide application strategies for clinical transfusion.

Key words: ABO blood group, ABO-mismatched, Platelet transfusion, Safety, Effectiveness

CLC Number:

R457

YANG Xuexin, WEI Yaming. The Current Situation and Suggestions of ABO-mismatched Platelet Transfusions[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(1): 17-22.

References

[1] BOUGIE D W,REESE S E,BIRCH R J,et al.Associations between ABO non-identical platelet transfusions and patient outcomes-a multicenter retrospective analysis[J].Transfusion,2023,63(5):960-972.
[2] ZULKEFLEE R H,HASSAN M N,HASSAN R,et al.Acute hemolytic transfusion reaction following ABO-mismatched platelet transfusion:two case reports[J].Transfus Apher Sci,2023,62(3):103658.
[3] 异基因造血干细胞移植临床输血专家共识起草专案组.异基因造血干细胞移植临床输血专家共识[J].临床输血与检验,2023,25(5):586-593.
[4] LOZANO M,HEDDLE N,WILLIAMSON L M,et al.Practices associated with ABO-incompatible platelet transfusions:a BEST Collaborative international survey[J].Transfusion,2010,50(8):1743-1748.
[5] DUNBAR N M,ORNSTEIN D L,DUMONT L J.ABO incompatible platelets:risks versus benefit[J].Curr Opin Hematol,2012,19(6):475-479.
[6] GUARENTE J,HARACH M,GOULD J,et al.Dilution is not the solution:acute hemolytic transfusion reaction after ABO-incompatible pooled platelet transfusion[J].Immunohematology,2019,35(3):91-94.
[7] YıLDıZ A,DOĞAN M,YALVAÇ M,et al.Platelet inventory and using out-of-group platelet suspension:a cost-effective strategy for a blood transfusion service[J].Hematol Oncol Stem Cell Ther,2023,16(4):337-341.
[8] PANDEY P,KUMARI S,MANDAL S,et al.A prospective observational study to compare transfusion outcomes in ABO identical versus ABO non-identical single donor platelet concentrates:an experience from a tertiary healthcare center in India[J].Transfus Clin Biol,2022,29(3):213-218.
[9] MALVIK N,LEON J,SCHLUETER A J,et al.ABO-incompatible platelets are associated with increased transfusion reaction rates[J].Transfusion,2020,60(2):285-293.
[10] PAVENSKI K,WARKENTIN T E,SHEN H,et al.Posttransfusion platelet count increments after ABO-compatible versus ABO-incompatible platelet transfusions in noncancer patients:an observational study[J].Transfusion,2010,50(7):1552-1560.
[11] DAS N,PRAKASH S,SAHU A,et al.Impact of dose and storage duration of platelet concentrates on platelet recovery between ABO identical and ABO non-identical random donor platelet transfusions in hemato-oncology patients[J].Hematol Transfus Cell Ther,2023:S2531-S1379(23)00038-X.
[12] 中国医师协会输血科医师分会,中华医学会临床输血学分会.特殊情况紧急抢救输血推荐方案[J].中国输血杂志,2014,27(1):1-3.
[13] 傅启华,王静.紧急抢救时ABO血型不相同血小板输注专家共识[J].中国输血杂志,2017,30(7):666-667.
[14] ZHU H J,MA Q Q,LI R S,et al.Blood group-related antigen Ley on human platelets and its involvement in platelet aggregation via a possible interaction with CD61[J].Transfusion,2020,60(9):2130-2138.
[15] SANT' ANNA GOMES B M,ESTALOTE A C,PALATNIK M,et al.Prevalence,serologic and genetic studies of high expressers of the blood group A antigen on platelets[J].Transfus Med,2010,20(5):303-314.
[16] 叶星晨. ABO血型非同型血小板输注[J].国际输血及血液学杂志,2015,38(2):182-184.
[17] DELELYS M E,OCHOA G,CSERTI-GAZDEWICH C M,et al.Relationship between ABO genotype and A antigen expression on platelets[J].Transfusion,2013,53(8):1763-1771.
[18] XU X G,XU F,YING Y L,et al.ABO antigen levels on platelets of normal and variant ABO blood group individuals[J].Platelets,2019,30(7):854-860.
[19] 凌霞,俞广舒,许先国.献血者血小板表面ABO血型抗原表达强度分析[J].中国输血杂志,2021,34(10):1069-1072.
[20] 曹开群,缪洪.血小板供应模式的应用价值探讨[J].健康必读,2018(35):212-214.
[21] 陆坷,李军.重庆主城区单采血小板供应现状及对策研究[J].国际检验医学杂志,2019,40(12):1515-1517.
[22] 梁明月,骆宏,黄伯泉,等.“取消互相献血” 政策对血小板供应的影响[J].当代医学,2020,26(22):20-22.
[23] 丁淑荣,张世翠.烟台地区2012年血液偏型紧张原因分析及对策[J].临床输血与检验,2014,16(1):89-90.
[24] 丁淑荣,张世翠.烟台地区2012年血液偏型紧张原因分析及对策[J].临床输血与检验,2014,16(1):89-90.
[25] 黄梅,郭晓明,文秀琼.2004—2008年绵阳市血液采供情况分析与对策[J].临床输血与检验,2010,12(2):159-161.
[26] MALVIK N,LEON J,SCHLUETER A J,et al.ABO-incompatible platelets are associated with increased transfusion reaction rates[J].Transfusion,2020,60(2):285-293.
[27] ZIELINSKI M D,SCHRAGER J J,JOHNSON P,et al.Multicenter comparison of emergency release group A versus AB plasma in blunt-injured trauma patients[J].Clin Transl Sci,2015,8(1):43-47.
[28] DUNBAR N M,YAZER M H,BIOMEDICAL EXCELLENCE FOR SAFER TRANSFUSION COLLABORATIVE AND THE STAT STUDY INVESTIGATORS.Safety of the use of group A plasma in trauma:the STAT study[J].Transfusion,2017,57(8):1879-1884.
[29] YAZER M H,SEHEULT J,KLEINMAN S,et al.Who’s afraid of incompatible plasma? A balanced approach to the safe transfusion of blood products containing ABO-incompatible plasma[J].Transfusion,2018,58(2):532-538.
[30] ZIELINSKI M D,JOHNSON P M,JENKINS D,et al.Emergency use of prethawed Group A plasma in trauma patients[J].J Trauma Acute Care Surg,2013,74(1):69-74;discussion 74-75.
[31] CHHIBBER V,GREENE M,VAUTHRIN M,et al.Is group A thawed plasma suitable as the first option for emergency release transfusion? (CME)[J].Transfusion,2014,54(7):1751-1755;quiz 1750.
[32] YAZER M,EDER A F,LAND K J.How we manage AB plasma inventory in the blood center and transfusion service[J].Transfusion,2013,53(8):1627-1633.
[33] NOVAK D J,BAI Y,COOKE R K,et al.Making thawed universal donor plasma available rapidly for massively bleeding trauma patients:experience from the Pragmatic,Randomized Optimal Platelets and Plasma Ratios (PROPPR) trial[J].Transfusion,2015,55(6):1331-1339.
[34] KAPLAN A,SEVCIK J,KISS J E.Low titer A plasma in three AB patients for therapeutic plasma exchange[J].J Clin Apher,2019,34(1):7-12.
[35] DANIEL-JOHNSON J,LEITMAN S,KLEIN H,et al.Probiotic-associated high-titer anti-B in a group A platelet donor as a cause of severe hemolytic transfusion reactions[J].Transfusion,2009,49(9):1845-1849.
[36] INABA S.Advancement in the preparation of red cell concentrates and platelet concentrates[J].Masui,2011,60(1):23-30.
[37] ROMPHRUK A V,CHEUNTA S,PAKOATE L,et al.Preparation of single donor platelet with low antibody titers for all patients[J].Transfus Apher Sci,2012,46(2):125-128.
[38] MATHUR A,SWAMY N,THAPA S,et al.Adding to platelet safety and life:platelet additive solutions[J].Asian J Transfus Sci,2018,12(2):136-140.
[39] BOJANIĆ I,LUKIĆ M,PLENKOVIĆ F,et al.Changes in the incidence of transfusion reactions in hematological patients over the past 30 years[J].Transfusion,2022,62(3):600-611.
[40] ADZAHAR S,HASSAN M N,ZULKAFLI Z,et al.Platelet additive solutions as an alternative storage medium of apheresis platelets to reduce ABO antibody titer for ABO-incompatibility platelet transfusion[J].Cureus,2023,15(8):e44012.
[41] REFAAI M A,FIALKOW L B,HEAL J M,et al.An association of ABO non-identical platelet and cryoprecipitate transfusions with altered red cell transfusion needs in surgical patients[J].Vox Sang,2011,101(1):55-60.
[42] ESTCOURT L J,STANWORTH S,DOREE C,et al.Different doses of prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation[J].Cochrane Database Syst Rev,2014(3):CD010984.
[43] TRIULZI D J,ASSMANN S F,STRAUSS R G,et al.The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia[J].Blood,2012,119(23):5553-5562.
[44] FONTAINE M J,WEBSTER J,GOMEZ S,et al.How do I implement an automated screen for high-titer ABO antibody as an inventory management tool for ABO plasma-incompatible platelets?[J].Transfusion,2015,55(12):2783-2789.
[45] 宋奎,许晓军,郭子文,等.造血干细胞移植患者血小板输注的疗效及影响因素[J].广东医学,2014,35(21):3393-3395.
[46] PARKHIDEH S,CHEGENI R,MEHDIZADEH M,et al.Effects of ABO incompatibility on the outcome of allogeneic hematopoietic stem cell transplantation[J].Transfus Apher Sci,2020,59(2):102696.
[47] STØY S,PATEL V C,STURGEON J P,et al.Platelet-leucocyte aggregation is augmented in cirrhosis and further increased by platelet transfusion[J].Aliment Pharmacol Ther,2018,47(10):1375-1386.
[48] 阳雪新,苑召虎,陈小洁,等.循环免疫复合物对血液病患者血小板输注疗效的影响[J].中国输血杂志,2022,35(4):404-408.
[49] 蔡晓红,雷航,王学锋. 2017年英国血液学标准委员会《血小板输注指南》和要点解读[J]. 诊断学理论与实践,2017,16(3):264-269.
[50] NEW H V,BERRYMAN J,BOLTON-MAGGS P H B,et al. Guidelines on transfusion for fetuses,neonates and older children[J]. Br J Haematol,2016,175(5):784-828.
[51] KAUFMAN R M,DJULBEGOVIC B,GERNSHEIMER T,et al.Platelet transfusion:a clinical practice guideline from the AABB[J]. Ann Intern Med,2015,162(3):205-213.
[52] 阳雪新,苑召虎,钟明璐,等.不同血液病患者血小板输注无效影响因素分析[J].岭南急诊医学杂志,2020,25(3):266-267.
[53] 郭芳,张琰,王改峰.重组人血小板生成素治疗免疫性血小板减少症的疗效及安全性观察[J].中国民康医学,2017,29(12):36-38.
[54] SLICHTER S J.Evidence-based platelet transfusion guidelines[J].Hematology Am Soc Hematol Educ Program,2007:172-178.
[55] JOSEPHSON C D,CASTILLEJO M I,GRIMA K,et al.ABO-mismatched platelet transfusions:strategies to mitigate patient exposure to naturally occurring hemolytic antibodies[J].Transfus Apher Sci,2010,42(1):83-88.
[56] PERSEGHIN P.High concentration plasma-reduced plateletapheresis concentrates[J].Transfus Apher Sci,2011,44(3):273-276.
[57] REFAAI M A,CARTER J,HENRICHS K F,et al.Alterations of platelet function and clot formation kinetics after in vitro exposure to anti-A and-B[J].Transfusion,2013,53(2):382-393.

The Current Situation and Suggestions of ABO-mismatched Platelet Transfusions

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

About

Author

Journal

Access Statistics

Contact

[1]	LIU Hong, MO Qin, MA Rongna, JIA Yao, WU Xiaofei, WANG Xun. The Effects of Riboflavin Concentrations and Visible Light Intensities on E. Coli in Plasma [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(1): 29-34.
[2]	YANG Xuexin, YUAN Yongmei, WU Zhaoyong, YUAN Zhaohu, LIU Zhen, TONG Xinxin, CHEN Xiaowei, WEI Yaming. The Preliminary Analysis of the Effectiveness and Safety of Minor ABO Incompatible Platelet Transfusions [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(1): 42-48.
[3]	ZHU Haiyang, HE Li, WANG Yongjun. Evaluation of an Improved Massive Transfusion Protocol in Orthotopic Liver Transplantation [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(6): 733-737.
[4]	YOU Laiwei, CHENG Yong, GUO Jianrong. Research Progress on the Influence of ABO Blood Group on Venous Thromboembolism in Cancer Patients [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(6): 857-861.
[5]	LIU Zheng, SUN Yamin, SHAO Shujun, et al. Analysis of HLA-I Antibody Specificity in Patients with Platelet Transfusion Refractoriness [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(5): 631-635.
[6]	ZHUO Hailong, SHAO Chunyan, LUO qun. Effect of Mixed Red Blood Cells with Different Proportions of Type A/O on Blood Group Antigen Identification [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(4): 475-479.
[7]	FAN Cuihua, ZHANG Jiandong, QIU Dongbiao, et al. The Construction and Application of Paperless Process in Clinical Transfusion [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(4): 528-532.
[8]	ZHAO Bin, TAO Qianshan, SHEN Yuanyuan, et al. Real-world Study of the Effectiveness of the R-CHOP Regimen in Treating Double-expressing Diffuse Large B-cell Lymphoma [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(4): 533-538.
[9]	ZHAO Lizhe, LI Jianping, LI Xiaofeng. The Relationship between Gut Microbiota and Human ABO Blood Group System [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(3): 297-301.
[10]	LI Zhengfeng, WANG Jia, CHEN Ping, et al. A Cross-sectional Study on the Distribution and Influencing Factors of Unexpected Antibody Positive Results in Pediatric Hospitalized Patients Planning to Receive Blood Transfusion [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(3): 374-378.
[11]	ZHAO Dongyan, SHEN Youhua, TIAN Zhibin, et al. Comparative Analysis of Causes of Deferred Blood Donation between Whole Blood and Aphaeresis Donors [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(3): 388-395.
[12]	XIANG Qian, REN Shi-hui, LI Xiao-ming. Efficacy and Safety of Therapy with Ixazomib in Patients with Multiple Myeloma: A Meta Analysis [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(2): 243-249.
[13]	CHENG Zhi-xiang, REN Lin, CAO Hong-rong, et al. Haemovigilance for Guideline-based Blood Transfusion Adverse Events [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(1): 48-55.
[14]	DAI Hua-you, LIU Kai-qiang, LIU Xiao-jie, et al. Analysis of Haemovigilance of Adverse Events in Blood Establishments from 2020 to 2021 [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(1): 56-62.
[15]	CHEN Rui, LV Meng-xing, YIN Jia-zhong, et al. The Transfusion Management in Children with Thalassemia：Safety Strategies in Yunnan Province [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(6): 710-715.